# antibodies -online.com





## anti-TANK antibody (AA 151-260) (Cy3)



Go to Product page

| $\sim$ |    |    |    |             |   |
|--------|----|----|----|-------------|---|
| ()     | VE | ۲۱ | /1 | $\triangle$ | Λ |

| Quantity:            | 100 μL  |
|----------------------|---|
| Target:              | TANK  |
| Binding Specificity: | AA 151-260  |
| Reactivity:          | Human   |
| Host:                | Rabbit  |
| Clonality:           | Polyclonal  |
| Conjugate:           | This TANK antibody is conjugated to Cy3   |
| Application:         | Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunofluorescence (Cultured Cells) (IF (cc)) |

#### **Product Details**

| Immunogen:            | KLH conjugated synthetic peptide derived from human TANK |  |
|-----------------------|--|--|
| Isotype:              | IgG  |  |
| Predicted Reactivity: | Human,Mouse,Rat  |  |
| Purification:         | Purified by Protein A.                                   |  |

### **Target Details**

| Target:           | TANK   |
|-------------------|--|
| Alternative Name: | TANK (TANK Products)   |
| Background:       | Synonyms: I TRAF, ITRAF, TRAF family member associated NF KAPPA B activator, TRAF family |

| member associated NFKB activator, TRAF in          | teracting protein, TRAF interacting protein TANK |
|--|--|
| isoform a, I-TRAF, Tank, TANK_HUMAN, TRA           | F family member-associated NF-kappa-B activator, |
| TRAF-interacting protein, TRAF interacting protein | rotein TANK isoform b, TRAF2.                    |

Background: TANK was initially identified as a novel TRAF-interacting protein that regulated TRAF-mediated signal transduction. Specifically, ligand binding by surface receptors in the tumor necrosis factor (TNF) receptor and Toll/interleukin-1 (IL-1) receptor families lead to the formation of a TRAF/TANK complex that mediates the activation of the transcription factor NF-kappaB. TANK is found in the cytoplasm and can bind to TRAF1, TRAF2, or TRAF3, thereby inhibiting TRAF function by sequestering the TRAFs in a latent state in the cytoplasm. For example, this protein can block TRAF2 binding to LMP1, the Epstein Barr virus transforming protein, and inhibit LMP1-mediated NF kappa B activation.

Pathways: p53 Signaling, TLR Signaling, Activation of Innate immune Response

#### **Application Details**

| Application Notes: | IF(IHC-P) 1:50-200 |
|--------------------|--------------------|
|                    | IF(IHC-F) 1:50-200 |
|                    | IF(ICC) 1:50-200   |

Restrictions: For Research Use only

### Handling

| Format:            | Liquid   |
|--------------------|--|
| Concentration:     | 1 μg/μL  |
| Buffer:            | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.         |
| Preservative:      | ProClin  |
| Precaution of Use: | This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only. |
| Storage:           | -20 °C   |
| Storage Comment:   | Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.                                  |
| Expiry Date:       | 12 months  |